Berkeley, California March. 29, 2022
Ian Vawter Joins as Vice President and Chief Financial Officer
Rebecca Furlong Joins as Vice President of U.S. Sales
Nital Patel Bryant Joins as Senior Director of Marketing
Channel Medsystems, Inc., a medical device company whose mission is to empower every woman to take control of her health journey, today announced the appointment of three new executive team members to amplify its commercialization efforts including: Ian Vawter, Vice President and Chief Financial Officer; Rebecca Furlong, Vice President of U.S. Sales; and Nital Patel Bryant, Senior Director of Marketing. These appointments follow the success of the company’s early commercial launch of its Cerene® Cryotherapy treatment for heavy menstrual bleeding in September 2021.
Ian Vawter brings 25 years of financial experience with a proven track record of building and managing financial, accounting and administrative operations for high growth private and public medical device companies. Most recently, Ian was Vice President and Chief Financial Officer of Tepha, Inc. (acquired by Becton, Dickson and Company), a proprietary biomaterials company developing and manufacturing medical devices for several end markets including women’s health.
Rebecca Furlong is a results-focused sales management executive with over 25 years of experience in medical devices and pharmaceuticals, including in women’s health. Most recently, she was an Area Vice President of Sales at Takeda, the largest pharmaceutical company in Asia, where she led a team responsible for $3 billion in annual contract sales of immunology products to leading hospitals, integrated delivery networks and infusion centers.
Nital Patel Bryant is a high impact marketing leader with a diverse 20 year track record of building brand recognition and sales momentum for medical devices, including women’s health products. Previously, she was the Director of Customer Marketing at GRAIL, where she led key marketing strategies to create awareness and adoption of the company’s early cancer detection product.
These executives were brought on to continue the momentum of the company’s initial market introduction of Cerene, a novel endometrial ablation option that uniquely facilitates the in-office treatment of heavy menstrual bleeding. The condition impacts more than 10 million women in the U.S. To date, more than 100 gynecologists have now completed training and performed initial procedures with the Cerene Cryotherapy Device.
Ric Cote, President and Chief Executive Officer of Channel Medsystems, commented, “We are thrilled to have Ian, Rebecca and Nital join our management team, which will enable us to continue to build on the momentum of our early commercial success. Physician interest in and feedback on Cerene has been very encouraging and offers us early insights into the value this treatment can provide for women suffering from heavy menstrual bleeding. Patients and physicians alike are very receptive to having these procedures performed in the office.”
Cerene was first introduced into the market by Channel Medsystems supported by a major financing closed in August 2021. This followed the successful completion of the company’s pivotal Clarity clinical trial and FDA approval of its PMA and PMA Supplement applications in 2019 and 2020, respectively.
About Cerene Cryotherapy
Cerene is an in-office endometrial cryoablation treatment that safely and effectively reduces heavy menstrual bleeding while naturally minimizing pain without requiring general anesthesia. The Cerene FDA pivotal clinical study (“Clarity”), recently published in The Journal of Minimally Invasive Gynecology, concluded that 90% of all patients experienced an improvement in bleeding symptoms and were satisfied with the procedure. Additionally, the use of cryoablation to treat the endometrium enabled the preservation of the uterine cavity, with visualization in 93% of evaluated patients, and the ability to evaluate for pathologic change in 96% of patients whose uterine cavities could be fully visualized.
About Channel Medsystems
Channel Medsystems® is a privately-held company dedicated to empowering every woman to take control of her health journey and live her best life. With a commitment to deliver innovative technologies that exceed the expectations of women and their gynecologists, Channel strives to develop easy-to-use, safe, and cost-effective medical devices, resulting in exceptional outcomes and superior patient comfort that are accessible to all women. Channel Medsystems, Inc. is headquartered in Berkeley, CA
Important Safety Information
Cerene® Cryotherapy Device is indicated to ablate the endometrial lining of the uterus in premenopausal women with heavy menstrual bleeding due to benign causes for whom childbearing is complete. Pregnancy following the Cerene procedure can be dangerous; therefore, contraception must be used until menopause. The Cerene procedure is not for those who have or suspect uterine cancer; have an active genital, urinary or pelvic infection; or an IUD. As with all surgical procedures, there are risks and considerations associated with the use of the Cerene Cryotherapy Device. Temporary side effects may include cramping, nausea, vomiting, vaginal discharge and spotting. For detailed benefit and risk information, consult the Cerene Instructions for use (IFU) or your healthcare professional. Learn More